CJC-1295 (with DAC)

Long-acting GHRH analogue with Drug Affinity Complex. Once or twice weekly GH pulse for sustained elevation.

Last updated: May 2026

What is CJC-1295 (with DAC)?

CJC-1295 with DAC (Drug Affinity Complex) is a modified form of Growth Hormone Releasing Hormone (GHRH) that includes a Drug Affinity Complex, a chemical modification that allows it to bind to albumin in the blood, dramatically extending its half-life from minutes to 6 to 8 days. Browse the full peptide library for related GH compounds.

This long half-life enables once or twice weekly dosing, creating what is known as a "GH bleed", a sustained elevation in growth hormone levels rather than sharp pulsatile spikes. This is fundamentally different from CJC-1295 without DAC, which produces short, natural-pattern GH pulses.

The sustained GH elevation from CJC-1295 with DAC is preferred by users seeking body composition changes (more muscle, less fat) over the long-term, as it maintains growth factor levels more consistently. For clean, pulsatile GH release, consider stacking with ipamorelin. For clinically validated visceral fat reduction, tesamorelin has FDA approval for that specific indication. However, some argue that constant GH elevation is less physiological than pulsatile release.

How It Works

GHRH Mimicry: CJC-1295 (with DAC) binds to the GHRH receptor in the pituitary gland, stimulating the release of growth hormone.

Albumin Binding: The DAC modification causes the peptide to bind to albumin (the most abundant blood plasma protein), protecting it from enzymatic degradation and extending its half-life to 6 to 8 days.

IGF-1 Elevation: Elevated GH stimulates the liver to produce IGF-1 (Insulin-like Growth Factor 1), which is responsible for many of GH's anabolic and regenerative effects in muscle and connective tissue.

Benefits

Once or twice weekly dosing convenience
Sustained GH and IGF-1 elevation
Improved lean muscle mass and body composition
Enhanced fat oxidation, especially visceral fat
Improved recovery and connective tissue health
Better sleep architecture
Anti-aging and skin quality improvements

Dosing Described in Research and Labels

Phase	Dose	Frequency	Duration
GH secretagogue (research)	No established human dose	Subcutaneous (research)	Not established

These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.

Side Effects

Common

⚠Water retention (can be significant)
⚠Tingling in hands and feet
⚠Fatigue in first 1 to 2 weeks
⚠Mild headaches
⚠Increased hunger

Rare

•Hypoglycemia (if injected near meal)
•Elevated cortisol in sensitive individuals
•Carpal tunnel syndrome with long-term high dose use

Who Should NOT Use CJC-1295 (with DAC)

✕Active cancer
✕Diabetic retinopathy
✕Pregnancy or breastfeeding
✕Poorly controlled diabetes

What to Expect

Week 1 to 2

Water retention noticeable. Sleep may improve. Mild fatigue as GH levels rise.

Week 3 to 6

Body composition begins shifting. Recovery faster. Skin quality improving.

Month 2 to 3

Clear anabolic effects. Lean mass increasing. Fat (especially visceral) decreasing.

Month 3+

Full benefits established. Most cycle 12 weeks on, 4 to 8 weeks off.

Notes from Ho Chi Minh City

CJC-1295 with DAC is the long-acting version, and the practical knock against it that surfaces repeatedly in the HCMC scene is fluid retention: the constant elevated GH bleed plus District 1 heat makes water retention the common reason users report moving to the no-DAC plus Ipamorelin route within a few months. The trade-off the format offers is convenience, a single weekly subcutaneous injection versus the daily no-DAC cadence, which is why it still appeals for longer bulking-oriented cycles where some retention matters less. Handling is descriptive but real: reconstituted peptide needs refrigeration rather than freezing, since HCMC temperature swings degrade it. On the Vietnam market the DAC version runs roughly 1.8 to 2.8 million VND per 5mg vial through cold-chain importers, slightly above the no-DAC equivalent due to the longer synthesis. Which version, dose, and cadence fit a given goal is a decision for a licensed prescriber.

Sourcing in Vietnam

CJC-1295 with DAC is not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Sourcing is research-grade only through cold-chain importers (1.8 to 2.8 million VND per 5mg vial). The DAC modification adds synthesis cost vs the no-DAC version. See the supplier list and COA guide before purchasing.

FAQ

Q: CJC-1295 with DAC or without DAC: which should I choose?

A: The two forms differ in pharmacology: the DAC version is long-acting and produces a sustained GH elevation, while the no-DAC version is short-acting and gives a more pulsatile, natural-pattern release. The trade-off the literature describes is convenience against more water retention with the sustained form. Which form suits a given goal, and how it is dosed, is a decision for a licensed prescriber.

Q: Should I combine CJC-1295 (with DAC) with Ipamorelin?

A: Yes, but note that with DAC the Ipamorelin is less critical than with the no-DAC version because CJC-DAC already provides sustained stimulation. Many users do add Ipamorelin doses 2 to 3x weekly for additional GH pulses. Source from the community-verified supplier list.

Where to Get CJC-1295 (with DAC) in Vietnam

See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.

View Supply Index

Related Peptides

CJC-1295 (no DAC)Ipamorelin Tesamorelin MOTS-c

Research & Sources

Long-acting albumin-binding GHRH analogues: insights into the design of CJC-1295 · Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · Journal of Clinical Endocrinology and Metabolism (2006) PMID: 16380436
Foundational paper describing the DAC modification and resulting extended half-life of CJC-1295.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 · Ionescu M, Frohman LA · Journal of Clinical Endocrinology and Metabolism (2006) PMID: 16940447
Clinical pharmacodynamic data supporting weekly dosing schedule of CJC-1295 with DAC.
Synergy between GHRH and a GH-releasing peptide for stimulation of GH release in humans · Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD · Journal of Clinical Endocrinology and Metabolism (2004) PMID: 15292313
Demonstrates synergistic GH release when GHRH analogues combine with GH secretagogues.
Effects of growth hormone secretagogues on body composition and bone mineral density · Sigalos JT, Pastuszak AW · Sexual Medicine Reviews (2018) PMID: 28526632
Reviews body composition and recovery outcomes from GH secretagogue protocols.

Important Disclaimer

Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.